BACKGROUND: Radiofrequency ablation (RFA) is a minimally invasive alternative in the treatment of bone tumors. Long-term follow-up has not been described in current literature. Detailed analysis of mid- and long-term follow-up after RFA treatment for a cohort of patients with low-grade cartilaginous tumors (atypical cartilaginous tumors and enchondroma) was performed. The results, complications, and development of halo dimensions over time are presented. METHODS: Data of all patients with an RFA procedure for an ACT between 2007-2018 were included. Ablation area is visible on baseline MRI, 3 months post-procedure, and is called halo. Volume was measured on MR images and compared to different follow-up moments to determine the effect of time on halo volume. Follow-up was carried out 3 months and 1, 2, 5, and 7 years after the procedure. Occurrence of complications and recurrences were assessed. RESULTS: Of the 137 patients included, 82 were analyzed. Mean follow-up time was 43.6 months. Ablation was complete in 73 cases (89.0%). One late complication occurred, while no recurrences were seen. Halo dimensions of height, width, and depth decreased with a similar rate, 21.5% on average in the first year. Subsequently, this decrease in halo size continues gradually during follow-up, indicating bone revitalization. CONCLUSION: RFA is a safe and effective treatment in low-grade cartilaginous tumors with an initial success rate of 89.0%. Extended follow-up shows no local recurrences and gradual substitution of the halo with normal bone.
BACKGROUND: Radiofrequency ablation (RFA) is a minimally invasive alternative in the treatment of bone tumors. Long-term follow-up has not been described in current literature. Detailed analysis of mid- and long-term follow-up after RFA treatment for a cohort of patients with low-grade cartilaginous tumors (atypical cartilaginous tumors and enchondroma) was performed. The results, complications, and development of halo dimensions over time are presented. METHODS: Data of all patients with an RFA procedure for an ACT between 2007-2018 were included. Ablation area is visible on baseline MRI, 3 months post-procedure, and is called halo. Volume was measured on MR images and compared to different follow-up moments to determine the effect of time on halo volume. Follow-up was carried out 3 months and 1, 2, 5, and 7 years after the procedure. Occurrence of complications and recurrences were assessed. RESULTS: Of the 137 patients included, 82 were analyzed. Mean follow-up time was 43.6 months. Ablation was complete in 73 cases (89.0%). One late complication occurred, while no recurrences were seen. Halo dimensions of height, width, and depth decreased with a similar rate, 21.5% on average in the first year. Subsequently, this decrease in halo size continues gradually during follow-up, indicating bone revitalization. CONCLUSION: RFA is a safe and effective treatment in low-grade cartilaginous tumors with an initial success rate of 89.0%. Extended follow-up shows no local recurrences and gradual substitution of the halo with normal bone.
Authors: V M van Praag Veroniek; A J Rueten-Budde; V Ho; P D S Dijkstra; M Fiocco; M A J van de Sande Journal: Surg Oncol Date: 2018-05-06 Impact factor: 3.279
Authors: Russell A Reeves; Matthew C DeWolf; Peter J Shaughnessy; James B Ames; Eric R Henderson Journal: Expert Rev Med Devices Date: 2017-10-04 Impact factor: 3.166
Authors: E F Dierselhuis; P J M van den Eerden; H J Hoekstra; S K Bulstra; A J H Suurmeijer; P C Jutte Journal: Bone Joint J Date: 2014-11 Impact factor: 5.082
Authors: Edwin F Dierselhuis; Jasper G Gerbers; Joris J W Ploegmakers; Martin Stevens; Albert J H Suurmeijer; Paul C Jutte Journal: J Bone Joint Surg Am Date: 2016-02-17 Impact factor: 5.284
Authors: Matthew D Bucknor; Viola Rieke; Youngho Seo; Andrew E Horvai; Randall A Hawkins; Sharmila Majumdar; Thomas M Link; Maythem Saeed Journal: Radiology Date: 2014-10-08 Impact factor: 11.105
Authors: Edwin F Dierselhuis; Jelle Overbosch; Thomas C Kwee; Albert J H Suurmeijer; Joris J W Ploegmakers; Martin Stevens; Paul C Jutte Journal: Skeletal Radiol Date: 2018-09-29 Impact factor: 2.199
Authors: Claudia Deckers; Bart H W Schreuder; Gerjon Hannink; Jacky W J de Rooy; Ingrid C M van der Geest Journal: J Surg Oncol Date: 2016-10-03 Impact factor: 3.454